ABSTRACT
INTRODUCTION
Hepatitis B virus (HBV) infection is a major global public health problem. Of the approximately 2 billion people who have been infected worldwide, more than 350-400 million remain infected chronically and become carriers of the virus (1) . The prevalence of HBV infection varies markedly in different geographic areas of the world, as well as in dif-ferent population subgroups (2) . Overall, about 5% of the population in Bulgaria is infected with HBV, in some districts reaching up to 7% (3), which places our country among the regions of the world with moderate prevalence (2-7%) of the virus but among those with higher rates in Europe.
The patient's immune response is one of the major factors influencing the viral eradication or chronification of the liver damage. The chronic course of HBV infection depends also on the host genetic factors and the virus itself -genotype and viral load.
The aim of our study was to investigate whether the cellular immune response of the newly diagnosed and treatment naïve chronic hepatitis B (CHB) patients may be influenced by the replicative status of HBV.
MATERIALS AND METHODS

Study subjects
We investigated 45 (17 female and 28 male) treatment naïve patients with chronic viral hepatitis B aged 42.48±13.19 years (19÷71 years). All patients were referred from the Department of Gastroenterology at the Clinic of Propaedeutics of Internal Diseases, University Hospital "Alexandrovska", Sofia, after clinical and laboratory evaluation according to predefined inclusion and exclusion criteria. The diagnosis of chronic hepatitis B was based on the recommendations of the American Association for Study of Liver Diseases. The results were compared to 29 ageand sex-matched healthy volunteers with normal liver function and negative serological markers for viral hepatitis. Prior to the evaluation, written informed consent for participation in the study was obtained from all patients and control subjects.
Cellular immunity
For the assessment of the cellular immunity, phenotyping of peripheral blood cells was performed using different combinations of monoclonal antibodies. The analysis was done with FACSCanto flowcytometer and FACSDiva software (Becton Dickinson, USA).
The following immune cells were investigated: total Т (CD3+) cells; helper-inducer (CD3+CD4+) and suppressor-cytotoxic (CD3+CD8+) T-cell subsets; В (CD19+) and NK (CD3-CD16+56+) cells; Tlymphocytes at different differentiation stages and functional characteristics: effector (cytotoxic and/ or memory T cells -CD8+CD28+), terminally differentiated cellular subpopulations with memory/ effector function (CD8+CD28-, CD8+CD57+), cellular populations with cytotoxic (CD8+CD11b-) and suppressor (CD8+CD11b+) potential; activated T-cells (CD3+HLA-DR+, CD8+HLA-DR+ and CD8+CD38+); T-lymphocytes with NK activity [NKT -CD3+CD(16+56+)].
Viral load
The quantitative evaluation of viremia was performed using ТaqMan quantitative RT-PCR (Applied Biosystem Real Time PCR primers and probe; Applied Biosystem 7300 RT-PCR system). The method is based on the detection of fluorescent signal generated by hydrolysis of a TagMan probe during target DNA amplification. For the generation of a reference curve four standards (Clonit HBV DNA complete genome) were used. The high sensitivity of the method (98%) allowed determining low hepatitis B viral load (≤100 copies/ml).
Statistical analysis
The comparative analysis of the cellular populations in different groups was performed using parametric (Student's t-test) and non-paramertic (MannWhitney) methods. The correlation analysis (viral load/cellular populations) was done by Spearman's rank correlations. The statistical analysis was performed using SPSS v. 16 . Values of Р<0.05 were considered statistically significant.
RESULTS
According to the viral load the investigated HBV patients were divided into two groups: group 1 -viral load >0 ÷ ≤10 4 copies/ml (25 patients) and group 2 -viral load > 10 4 ÷ ≤ 10 8 copies/ml (17 patients). No patients with extremely high viremia (>10 8 copies/ml) were diagnosed during the study. The results of immunophenotyping are presented in Table 1 .
Our data (Table 1) showed similar alterations in both groups of patients as compared to healthy controls which could be summarized as it follows:
1. As a whole, no significant differences in the studied immune parameters were observed between both patients' groups with the exception of significantly higher values of CD4+ T cells and a trend of more pronounced reduction of CD8+ T-cell subsets in individuals with higher as compared to those with lower rate of viral replication. These disturbances lead to a markedly higher (p=0.031) CD4/CD8 ratio in patients with viral load >10 4 copies/ml in comparison to those with DNA HBV levels ≤ 10 4 copies/ml. As another approach to test whether the viral replication rate could influence the cellular immunity of patients with chronic HBV infection, we have performed a correlation analysis between the level of viremia and the values of the investigated cell subsets. No statistically significant correlations were found between the HBV replication rate and the cellular immune alterations.
DISCUSSION
In the majority of cases the HBV infection is self-limiting due to the fact that effective immune responses from innate and adaptive immune systems can lead to complete clearance of the virus or at least to suppression of viral replication. Studies have revealed that T-cellular immune reactivity is essential for the disease pathogenesis. Powerful CD8 immune response has been proven in patients with spontaneous eradication of HBV, and in those with chronic disease evolution this reactivity is much weaker or absent (4, 5, 6) . Тhe effector cell dysfunction is one of the main factors for the chronic evolution of infection. Тhe chronic course of the disease is associated with multiple defects in T-cellular immunity correlating with the viral replication (7). The higher HBV DNA levels inhibit both CD4+ and CD8+ Т-cells (8) and these alterations increase the risk for liver dysfunction, disease chronification, liver cirrhosis and hepatocellular carcinoma. It should be taken into consideration that the interpretation of viral load data and comparison of results have been complicated by the inconsistency among the various units of measure for HBV DNA and the different criteria for grading the level of viral replication. A study in India (9) divided the HBV patients into two groups according to their viral loads (lower -<2000 IU/ml and higher ->2000 IU/ml) and found decreased total T-cell counts in both patients' groups as compared to healthy individuals. Additionally, subjects with higher viral replication demonstrated a decrease of cytotoxic T-cells in comparison to controls, whereas such differences were not observed in individuals with lower HBV DNA levels. Using another approach for the classification of viral load Xibing et al. (10) found elevated numbers of specific cytotoxic Tlymphocytes and NK cells, and decreased non-specific cytotoxic T-cell subsets in the group with lower (HBV DNA 10 4 -10 5 copies/ml) compared to this with higher (10 6 -10 7 copies/ml) rate of viral replication. You et al. (11, 12) described negative correlation between the levels of HBV DNA on one hand, and CD4+ cells and CD4/CD8 ratio -on the other hand. On the contrary, their data revealed positive correlation of CD8+ cells with viral load.
The results of our study showed no differences between the two groups of CHB patients (with low ≤10 4 copies/ml and high >10 4 -10 8 copies/ml viral DNA levels) concerning the studied cellular immune parameters. In both patients' groups we observed marked T-cell deficiency. These findings are consistent with the results of Mukherjee et al. (9), but do not comply with those of others authors (11, 12) . The detailed analysis of T-lymphocytes according to differentiation stages and functional characteristics revealed decreased cell subpopulations with putative cytotoxic potential (CD8+CD11b-and CD8+CD28+) in both patients' groups compared to healthy controls. These results correlate with the reported reduced nonspecific cytotoxic T-cells in chronic hepatitis B (9). It should be pointed out that Sun et al. (13) established increased percentages of CD8+CD28-subset in the CD8+ population in CHB correlating with the levels of viral DNA. In line with the above mentioned observations Li et al. (14) described decreased CD8+CD28+/CD8+CD28-T-cells ratio in CHB patients compared to healthy controls due to elevated values of CD8+CD28-cell subset and associated with HBV loads. In contrast to the abovementioned data, no alterations of CD8+CD28-cell subsets in CHB were found by us. A possible explanation of the observed discrepancies could be attributed to the different approaches of cell subset analysis -in the lymphocytes in our study or within the Tcell population in the other investigations. It is interesting to note the decreased levels of T-cells expressing different activation markers (CD3+HLA-DR+, CD8+CD38+) found in our HBV positive patients (regardless of viral loads) in comparison to healthy controls. Cao et al. (15) established significant positive association between the CD8+CD38+ T-cell proportions and serum HBV DNA, while Nikolova et al. (16) reported the lack of such correlation. It should be also noted that Ye et al. (17) observed lower proportions of activated CD38+ T cells in patients with non-recovered acute-on-chronic liver failure (ACLFs) (characterized by higher HBV DNA levels)
